Author: admin

DelveInsight’s, “Hypertension Pipeline Insight, 2026” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Hypertension pipeline landscape. It covers the Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hypertension pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Hypertension Treatment Landscape @ https://www.delveinsight.com/sample-request/hypertension-pipeline-insight

Key Takeaways from the Hypertension Pipeline Report

• On February 20, 2026- Merck Sharp & Dohme LLC conducted a study medicine designed to treat PAH. It is a targeted therapy, which is a treatment that works on certain proteins that play a role in causing PAH. This is a long-term follow-up (LTFU) study. People who took part in certain other studies testing sotatercept for PAH may be able to join this study. The goal of this study is to learn about the long-term safety of sotatercept and if people tolerate it when taken with standard PAH treatment over a longer period of time.
• On February 13, 2026- Actelion initiated a study to confirm the selexipag starting dose(s), selected based on pharmacokinetic (PK) extrapolation from adults, that leads to similar exposure as adults doses in children from greater than or equal to (>=) 2 to less than (˂) 18 years of age with Pulmonary Arterial Hypertension (PAH), by investigating the PK of selexipag and its active metabolite ACT-333679 in this population.
• DelveInsight’s Hypertension pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Hypertension treatment.
• The leading Hypertension Companies such as Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc, Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical and others.
• Promising Hypertension Pipeline Therapies such as Ramipril and hydrochlorothiazide, Liraglutide , Nebivolol, Metoprolol XL, Aliskiren and HCTZ, Bunazosin, Doxazosin, Valsartin, losartan potassium and others.

Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Hypertension Ongoing Clinical Trials Assessment

The Hypertension Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Hypertension Pipeline Report also highlights the unmet needs with respect to the Hypertension.

Hypertension Overview

Hypertension, commonly known as high blood pressure, is a chronic medical condition characterized by elevated pressure in the arteries, which can lead to serious health complications if left untreated. It is classified into primary hypertension, which has no identifiable cause and often develops gradually over many years, and secondary hypertension, which results from an underlying condition, such as kidney disease or hormonal disorders.

Hypertension Emerging Drugs Profile

• Seralutinib: Gossamer Bio

Seralutinib, developed by Gossamer Bio, is an inhaled medication designed to treat pulmonary arterial hypertension (PAH). It functions as an antagonist of several receptors, including platelet-derived growth factor receptors (PDGFRα and PDGFRβ), colony-stimulating factor 1 receptor (CSF1R), and c-KIT. This multi-target approach aims to mitigate the inflammatory and proliferative pathways that contribute to pulmonary vascular remodeling associated with PAH. Currently, the drug is in the Phase III stage of its development for the treatment of Pulmonary Arterial Hypertension.

• AD-209: Addpharma Inc.

AD-209 is an investigational drug developed by Addpharma Inc., primarily targeting hypertension. It is part of a broader pipeline that includes various innovative medicines aimed at treating multiple conditions, including hyperlipidemia and diabetes. Currently, the drug is in the Phase III stage of its development for the treatment of Hypertension.

• Zilebesiran: Alnylam Therapeutics

Zilebesiran is an investigational RNA interference (RNAi) therapeutic developed by Alnylam Therapeutics, specifically targeting hypertension. It is designed to inhibit the synthesis of angiotensinogen (AGT), a key precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a crucial role in blood pressure regulation. Zilebesiran works by utilizing RNAi technology to selectively reduce the production of AGT in the liver. This reduction leads to decreased levels of angiotensin II, a potent vasoconstrictor that contributes to elevated blood pressure. By lowering AGT synthesis, zilebesiran aims to achieve sustained reductions in blood pressure over time. Currently, the drug is in the Phase II stage of development to treat Hypertension.

• LAM-001: ORPHAI THERAPEUTICS

LAM-001 is an investigational inhaled formulation of sirolimus (also known as rapamycin) developed by OrphAI Therapeutics. It is designed specifically for the treatment of pulmonary hypertension (PH) and bronchiolitis obliterans syndrome (BOS), conditions that can significantly impact lung function and patient quality of life. Currently, the drug is in the Phase II stage of development to treat Pulmonary Hypertension.

• HS135: 35Pharma Inc.

HS135 is an investigational drug developed by 35Pharma Inc., focusing on the treatment of pulmonary hypertension (PH) and related cardiometabolic diseases. It is a multi-specific receptor ectodomain ligand trap designed to neutralize activins and growth differentiation factors (GDFs), which are validated drivers of these conditions. HS135 functions as a ligand trap that specifically targets and inhibits the activity of activins and GDFs, particularly activin A and GDF-8. By doing so, it aims to rebalance the signaling pathways involved in various pathologies associated with pulmonary hypertension and obesity-related heart failure. Currently, the drug is in the Phase I stage of development to treat Pulmonary Arterial Hypertension.

Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Hypertension Unmet Needs

The Hypertension Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Hypertension with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypertension Treatment.
• Hypertension Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypertension market

Hypertension Companies

Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc, Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical and others.

Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Hypertension Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

See the latest progress in drug development and clinical research @ Hypertension Market Drivers and Barriers, and Future Perspectives

Scope of the Hypertension Pipeline Report

• Coverage- Global
• Hypertension Companies- Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc, Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical and others.
• Hypertension Pipeline Therapies- Ramipril and hydrochlorothiazide, Liraglutide, Nebivolol, Metoprolol XL, Aliskiren and HCTZ, Bunazosin, Doxazosin, Valsartin, losartan potassium and others.
• Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Cardiovascular Diseases Research–Access the Full Hypertension Pipeline Analysis Today! @ Hypertension Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Hypertension: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hypertension – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Seralutinib: Gossamer Bio
9. Mid Stage Products (Phase II)
10. Zilebesiran: Alnylam Therapeutics
11. Early Stage Products (Phase I)
12. HS135: 35Pharma Inc.
13. Preclinical and Discovery Stage Products
14. Drug name: Company name
15. Inactive Products
16. Hypertension Key Companies
17. Hypertension Key Products
18. Hypertension- Unmet Needs
19. Hypertension- Market Drivers and Barriers
20. Hypertension- Future Perspectives and Conclusion
21. Hypertension Analyst Views
22. Hypertension Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/hypertension-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hypertension Treatment Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “HER2-Negative Breast Cancer Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in HER2-Negative Breast Cancer pipeline landscape. It covers the HER2-Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2-Negative Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive HER2-Negative Breast Cancer Pipeline Report @ https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight

Key Takeaways from the HER2-Negative Breast Cancer Pipeline Report

• On February 23, 2026- Institut Curie conducted a phase II trial will evaluate the combination of tucatinib, a HER2 TKI, and trastuzumab, a HER2-directed antibody in patients with a HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation. To demonstrate the actionability of ERBB3 mutations, all patients will receive a combination of trastuzumab and tucatinib, in 3-weeks cycles.
• On February 19, 2026- Merck Sharp & Dohme LLC announced a phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer.
• DelveInsight’s HER2-Negative Breast Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for HER2-Negative Breast Cancer treatment.
• The leading HER2-Negative Breast Cancer Companies such as Genentech, CytomX Therapeutics, H3 Biomedicine, Regor Therapeutics, Immutep Limited, Merck & Co, Klus Pharma, Olema Pharmaceuticals, BeiGene, AstraZeneca, Janssen/Merck/GSK, Ono Pharmaceutical, Laekna Therapeutics, NanoMab, InSilico Medicine, TYK Medicine, Shanghai Pharmaceutical Group, Verastem Oncology, Allarity Therapeutics, Shenzhen Yangli Pharmaceutical Technology, Phoenix Molecular Designs, and others.
• Promising HER2-Negative Breast Cancer Therapies such as Doxorubicin, Cyclophosphamide, Utidelone Combined with Bevacizumab, Capecitabine, Carboplatin, Cisplatin, and others.

Access DelveInsight’s in-depth HER2-Negative Breast Cancer Pipeline Analysis for a closer look at promising breakthroughs @ HER2-Negative Breast Cancer Clinical Trials and Studies

The HER2-Negative Breast Cancer Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The HER2-Negative Breast Cancer Pipeline Report also highlights the unmet needs with respect to the HER2-Negative Breast Cancer.

HER2-Negative Breast Cancer Overview

Breast Cancer is the world’s most common disease in women, and is also a major factor that leads to death. It is reported that 5% of patients with breast cancer have distant metastasis at a diagnosis, and 30% of patients with early cancer subsequently experience the distant metastasis. Metastatic breast cancer cannot be completely cured; however, significant improvement in the survival period was observed consistent with the emergence of novel therapy. The purpose of the treatment for metastatic breast cancer is to prolong the survival period and improve the cancer patients’ quality of life (QOL) by managing cancer-related symptoms. To that end, not the same strategy for all patients but individual approach for each patient should be used. When a breast cancer is HER2-negative, it means that the cancerous cells do not contain high levels of the protein HER2.

HER2-Negative Breast Cancer Emerging Drugs Profile

• Giredestrant : Genentech

Giredestrant is a novel investigative small molecule that works as selective estrogen receptor degrader (SERD) by targeting the estrogen receptor (ER). The drug candidate is a new molecular entity (NME) which is administered through oral route. Preclinical studies suggest that Giredestrant is orally bioavailable and competitively inhibits the binding of estrogen to the ER. In preclinical models, Giredestrant has been shown to restrain the normally dynamic behavior of both wild-type and mutant ER, immobilizing the ER and attenuating the expression of its target genes. Currently, the drug is in Phase III stage of its development for the treatment of HER2 negative breast cancer.

• Inavolisib : Genentech

Inavolisib is an investigational small molecule designed to selectively inhibit mutant PI3Kα. In preclinical models, the molecule showed potent selective inhibition of PI3Kα and has increased potency to mutant PI3K cells over wild type. It is less sensitive for the other three PI3K isoforms. Inavolisib binds to the ATP-binding site of PI3Kα, thereby blocking phosphorylation of PIP2 to PIP3 and preventing downstream signaling as shown in preclinical models. Moreover, inavolisib specifically degrades the mutant form of PI3Kα, resulting in reduction of pathway activity. Currently the drug is in Phase III stage of its development for the treatment of HER2 negative breast cancer.

• CX-2009 : CytomX Therapeutics

CX-2009 (Praluzatamab ravtansine) is a conditionally activated antibody-drug conjugate (ADC) comprised of a CD166-directed humanized monoclonal antibody conjugated to the maytansinoid DM4, a tubulin inhibitor. Praluzatamab ravtansine utilizes CytomX Probody® platform technology, which incorporates a masking peptide to cover and block the cellular binding region of the antibody. Tethered to the antibody via a protease-cleavable linker, currently, the drug is in Phase II stage of its development for the treatment of HER2 negative breast cancer.

• H3B 6545 : H3 Biomedicine

H3B-6545 is an oral, selective estrogen receptor covalent antagonist (SERCA) for the research of metastatic ER-positive, HER2-negative breast cancer. H3B- 6545, a first-in-class small molecule selective estrogen receptor covalent antagonist (SERCA) demonstrates activity in tumor models that harbor wild-type or mutant ERα.4 H3B-6545 activity against ERα mutants resistant to standard therapy provides an opportunity to target a currently unmet medical need both as a single agent and in combination with other breast cancer therapies. Currently, the drug is in Phase II stage of its development for the treatment of HER2 negative breast cancer.

• RGT-419B : Regor Therapeutics

RGT-419B is a new generation of CDK inhibitor with an optimized kinase activity spectrum. Results from non-clinical studies showed that RGT-419B demonstrated full suppression of ER+ breast cancer cell proliferation with acquired resistance to CDK4/6 inhibitors. Additionally, RGT-419B’s tumor cell suppression was further augmented when combined with a selective estrogen receptor down-regulator or a PI3K signaling pathway inhibitor. Currently, the drug is in Phase I stage of its development for the treatment of HER2 negative breast cancer.

Explore DelveInsight’s expert-driven report today! @ HER2-Negative Breast Cancer Unmet Needs

The HER2-Negative Breast Cancer pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of HER2-Negative Breast Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2-Negative Breast Cancer Treatment.
• HER2-Negative Breast Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• HER2-Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HER2-Negative Breast Cancer market.

HER2-Negative Breast Cancer Companies

Genentech, CytomX Therapeutics, H3 Biomedicine, Regor Therapeutics, Immutep Limited, Merck & Co, Klus Pharma, Olema Pharmaceuticals, BeiGene, AstraZeneca, Janssen/Merck/GSK, Ono Pharmaceutical, Laekna Therapeutics, NanoMab, InSilico Medicine, TYK Medicine, Shanghai Pharmaceutical Group, Verastem Oncology, Allarity Therapeutics, Shenzhen Yangli Pharmaceutical Technology, Phoenix Molecular Designs, and others.

HER2-Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

HER2-Negative Breast Cancer Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming HER2-Negative Breast Cancer Therapies and key Developments @ HER2-Negative Breast Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the HER2-Negative Breast Cancer Pipeline Report

• Coverage- Global
• HER2-Negative Breast Cancer Companies- Genentech, CytomX Therapeutics, H3 Biomedicine, Regor Therapeutics, Immutep Limited, Merck & Co, Klus Pharma, Olema Pharmaceuticals, BeiGene, AstraZeneca, Janssen/Merck/GSK, Ono Pharmaceutical, Laekna Therapeutics, NanoMab, InSilico Medicine, TYK Medicine, Shanghai Pharmaceutical Group, Verastem Oncology, Allarity Therapeutics, Shenzhen Yangli Pharmaceutical Technology, Phoenix Molecular Designs, and others.
• HER2 Negative Breast Cancer Therapies- Doxorubicin, Cyclophosphamide, Utidelone Combined with Bevacizumab, Capecitabine, Carboplatin, Cisplatin, and others.-
• HER2-Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HER2-Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight’s exclusive HER2-Negative Breast Cancer Pipeline Report—access it now! @ HER2-Negative Breast Cancer Emerging Drugs and Major Companies

Table of Content

1. Introduction
2. Executive Summary
3. HER2 Negative Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HER2 Negative Breast Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Giredestrant : Genentech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CX-2009 : CytomX Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. RGT-419B : Regor Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. HER2 Negative Breast Cancer Key Companies
21. HER2 Negative Breast Cancer Key Products
22. HER2 Negative Breast Cancer- Unmet Needs
23. HER2 Negative Breast Cancer- Market Drivers and Barriers
24. HER2 Negative Breast Cancer- Future Perspectives and Conclusion
25. HER2 Negative Breast Cancer Analyst Views
26. HER2 Negative Breast Cancer Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/her2-negative-breast-cancer-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HER2-Negative Breast Cancer Clinical Trial Pipeline Expands as 70+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Hepatocellular Carcinoma Pipeline Insight 2026 report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in the Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Hepatocellular Carcinoma Treatment Landscape @ https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight

Key Takeaways from the Hepatocellular Carcinoma Pipeline Report

• On February 05, 2026, Merck Sharp & Dohme LLC conducted a phase 3 study is to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3745) versus lenvatinib in combination with placebo as first-line therapy for the treatment of advanced hepatocellular carcinoma in adult participants.
• On February 05, 2026, Coherus Oncology Inc. announced a phase 2 study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.
• On February 03, 2026, UNICANCER initiated a Phase II/III Randomized Study Comparing Durvalumab and Tremelimumab +/- Hepatic Arterial Infusion Chemotherapy With GEMOX in Hepatocellular Carcinoma With High Tumor burden.
• DelveInsight’s Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.
• The leading Hepatocellular Carcinoma Companies such as Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others
• Promising Hepatocellular Carcinoma Therapies such as Pembrolizumab, Tislelizumab, HLX53 (1000mg), Atezolizumab, Bevacizumab, Tiragolumab, Nivolumab and others.

Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Hepatocellular Carcinoma Clinical Trials Assessment

The Hepatocellular Carcinoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Hepatocellular Carcinoma Pipeline Report also highlights the unmet needs with respect to Hepatocellular Carcinoma.

Hepatocellular Carcinoma Overview

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection. Cirrhosis is a significant step in viral carcinogenesis for hepatocellular carcinoma. Integration of the hepatitis B virus genome into the host genome is the primary pathogenesis for oncogenesis in HBV. Insertion of viral genome in telomerase reverse transcriptase (TERT) promoter sites of the human genome resulting in mutation accounting for 60% of HCC cases. Other genetic alterations include mutations in TP53 (affecting cell cycle), beta-1 catenin (CTNNBI), axis inhibitor-1 (AXINI), AT-rich interaction domain-containing protein 1A (ARID1A), and ARID2(chromatin proliferation).

Hepatocellular Carcinoma Emerging Drugs

• Namodenoson: Can-Fite BioPharma

Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5′- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). The drug had been out-licensed to Chong Kun Dang (CKD) Pharmaceutical in Korea and to CMS in China.for the treatment of Hepatocellular Carcinoma and NASH. A Phase I/II study in hepatocellular carcinoma (HCC) successfully met its primary and secondary endpoints demonstrating initial indications for efficacy of Namodenoson. A global Phase II study treating patients with Namodenoson as a second-line therapy has recently been concluded.

• SRF388: Surface Oncology

SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. IL-27 is an immunosuppressive cytokine involved in resolving T cell mediated inflammation. Recent data points to IL-27 as a master regulator of the expression of co-inhibitory receptors expressed on CD4+ and CD8+ T cells. Elevated levels of IL-27 transcripts and mRNA gene signatures are found in cancer and are associated with poor prognoses. Surface Oncology has identified particular tumor types where IL-27 appears to play an important role in the immunosuppressive tumor microenvironment and may contribute to resistance to treatment with checkpoint inhibitors.

• Porustobart: Harbour BioMed

Porustobart (HBM4003) is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from mice. By enhancing antibody-dependent cell cytotoxicity (ADCC) killing activity, porustobart has demonstrated significantly improved depletion specific to high CTLA-4 Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug in monotherapy and combo-therapy.

• Fisogatinib: CStone Pharmaceuticals

Fisogatinib is an orally available, potent, irreversible inhibitor of FGFR4. Fisogatinib was specifically designed to inhibit FGFR4 with exquisite selectivity, thereby sparing the paralogs FGFR1, FGFR2 and FGFR3 and preventing potential adverse effects. Preclinical data has validated FGFR4 as an oncogenic driver for a subset of patients with advanced HCC. The US Food and Drug Administration has granted orphan drug designation to fisogatinib for the treatment of HCC. Fisogatinib is being investigated in the Phase I/II stage of its development for the treatment of patients with FGFR4-activated HCC.

• STP705: Sirnaomics

STP705 is composed of two siRNA oligonucleotides targeting TGF-β1 and COX-2 mRNA respectively and formulated in nanoparticles with a proprietary Histidine-Lysine Co-Polymer (HKP) peptide. Each individual siRNA has demonstrated the ability to inhibit the expression of their target mRNA and combining the two siRNAs produces a synergistic effect that diminishes pro-fibrogenic, pro-inflammatory, and pro-tumorigenic factors. Sirnaomics has completed several pre-clinical studies that demonstrate that inhibition of TGF-β1 and COX-2 and is expected to result in the inhibition of tumor growth and provide an alternative approach for the treatment of various Hepatocellular Carcinomas. Molecular analyses of the effects of administering the combination demonstrated that the inhibition of these targets had effects on downstream gene products associated with numerous oncology targets.

Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Hepatocellular Carcinoma Unmet Needs

The Hepatocellular Carcinoma Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Hepatocellular Carcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatocellular Carcinoma Treatment.
• Hepatocellular Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hepatocellular Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatocellular Carcinoma market.

Hepatocellular Carcinoma Companies

Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others.

Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

See the latest progress in drug development and clinical research @ Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Hepatocellular Carcinoma Pipeline Report

• Coverage- Global
• Hepatocellular Carcinoma Companies- Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others
• Hepatocellular Carcinoma Therapies- Pembrolizumab, Tislelizumab, HLX53 (1000mg), Atezolizumab, Bevacizumab, Tiragolumab, Nivolumab, and others
• Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research–Access the Full Hepatocellular Carcinoma Pipeline Analysis Today! @ Hepatocellular Carcinoma Drugs and Companies

Table of Content

1. Introduction

2. Executive Summary

3. Hepatocellular Carcinoma: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Hepatocellular Carcinoma- DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Namodenoson: Can-Fite BioPharma

9. Drug profiles in the detailed report…..

10. Mid Stage Products (Phase II)

11. SRF388: Surface Oncology

12. Drug profiles in the detailed report…..

13. Early Stage Products (Phase I)

14. STP705: Sirnaomics

15. Drug profiles in the detailed report…..

16. Preclinical and Discovery Stage Products

17. Drug name: Company name

18. Drug profiles in the detailed report…..

19. Inactive Products

20. Hepatocellular Carcinoma Key Companies

21. Hepatocellular Carcinoma Key Products

22. Hepatocellular Carcinoma- Unmet Needs

23. Hepatocellular Carcinoma- Market Drivers and Barriers

24. Hepatocellular Carcinoma- Future Perspectives and Conclusion

25. Hepatocellular Carcinoma Analyst Views

26. Hepatocellular Carcinoma Key Companies

27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/hepatocellular-carcinoma-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatocellular Carcinoma Clinical Trial Pipeline Shows Potential with Active Contributions from 90+ Key Companies | DelveInsight

DelveInsight’s, “Hepatitis B Virus Infection Pipeline Insight 2026” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Hepatitis B Virus (HBV) Infection pipeline landscape. It covers the Hepatitis B Virus Infection pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatitis B Virus therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Hepatitis B Virus Infection Pipeline. Dive into DelveInsight’s comprehensive report today! @ https://www.delveinsight.com/sample-request/hepatitis-b-virus-hbv-infection-pipeline-insight

Key Takeaways from the Hepatitis B Virus Infection Pipeline Report

• On February 19, 2026- University of North Carolina, Chapel Hill conducted a study design is a randomized, double-blind, placebo-controlled trial among two groups of mother-infant dyads: women who receive TDF vs placebo in late pregnancy and the postpartum period (beginning at 28-32 weeks’ gestation and continuing through 4 weeks’ postpartum). While official World Health Organization (WHO) recommendations are to continue TDF at least through delivery, a range from delivery through 12 weeks’ postpartum is possible; the investigators will continue therapy through 4 weeks’ postpartum in this study.
• On February 15, 2026, Shanghai Argo Biopharmaceutical Co., Ltd. initiated a Phase II Study to Evaluate the Efficacy and Safety of BW-20507 Injection Combined With Pegylated Interferon Alfa in Patients With Chronic Hepatitis B Infection.
• DelveInsight’s Hepatitis B Virus Infection pipeline report depicts a robust space with 80+ active players working to develop 90+ pipeline therapies for Hepatitis B Virus Infection treatment.
• The leading Hepatitis B Virus Infection Companies such as Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics and others.
• Promising Hepatitis B Virus Infection Pipeline Therapies such as Peginterferon Alfacon-2, Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni], Entecavir, Tenofovir disoproxil fumarate (TDF), Bepirovirsen and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hepatitis B Virus Infection Treatment Drugs

The Hepatitis B Virus Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Hepatitis B Virus Pipeline Report also highlights the unmet needs with respect to the Hepatitis B Virus.

Hepatitis B Virus Overview

Hepatitis B viral infection is a serious global healthcare problem. It is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). Hepatitis B virus is transmitted via percutaneous inoculation or through mucosal exposure with infectious bodily fluids. Oral-fecal transmission is possible but considerably rare.

Hepatitis B Virus Infection Emerging Drugs Profile

• Bepirovirsen: GSK

Bepirovirsen is an investigational antisense oligonucleotide (ASO) designed to specifically recognise the RNA that the hepatitis B virus uses to replicate itself in the infected liver cells (hepatocytes) and make the viral antigens (proteins) which facilitate chronicity of the disease by helping to avoid clearance by the immune system. The ASO recruits the liver’s own enzymes to eliminate the RNA by digesting it to an inactive form. The subsequent reduction in the levels of the RNA results in a decrease in both the virus and the production of viral antigen (HBsAg) by the hepatocytes, which can be measured by a drop in the HBV DNA and antigen levels in the circulating blood. Bepirovirsen has an additional property of stimulating immune responses via Toll-like receptor 8 (TLR8) which may help the immune system to achieve durable clearance of the virus from circulating blood.

Bepirovirsen (previously known as ‘ISIS 505358 or IONIS-HBVRX’) was discovered by and jointly developed with Ionis Pharmaceuticals. Bepirovirsen is one of the ASO HBV programme assets in-licensed by GSK from Ionis Pharmaceuticals in August 2019. Currently, the drug is in the Phase III stage of its development for the treatment of Hepatitis B Virus Infection.

• VIR 2218: Vir Biotechnology

VIR-2218 is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials. Currently, the drug is in the Phase II stage of its development for the treatment of Hepatitis B Virus Infection.

• AB 729: Arbutus Biopharma

AB-729 is a subcutaneously-delivered RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus. AB-729 targets hepatocytes using the novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology. AB-729 is currently being evaluated in a Phase IIa randomized, open-label, proof-of-concept clinical trial in combination with ongoing standard-of-care nucleos(t)ide analog therapy and short courses of Peg-IFNα-2a in 40 patients with chronic HBV infection.

• AHB-137: Ausper Biopharma

AHB-137 is an unconjugated antisense oligonucleotide (ASO) with the potential to be a backbone for the functional cure of CHB. In June 2023, AusperBio announced that the Center for Drug Evaluation (CDE) of China has approved the Investigational New Drug (IND) application of AHB-137 to treat chronic hepatitis B (CHB) aiming for functional cure. AHB-137’s highly potent antiviral activity in preclinical studies, along with its favorable pharmacokinetics and safety profile, garnered significant attention and recognition. Currently, the drug is in the Phase I stage of its development for the treatment of Hepatitis B Virus Infection.

Explore groundbreaking therapies and clinical trials in the Hepatitis B Virus Infection Pipeline @ New Hepatitis B Virus Infection Drugs

Hepatitis B Virus Infection Companies

Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics and others.

The Hepatitis B Virus Infection Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Hepatitis B Virus Infection with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatitis B Virus Infection Treatment.
• Hepatitis B Virus Infection Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hepatitis B Virus Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatitis B Virus Infection market

Hepatitis B Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Hepatitis B Virus Infection Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Hepatitis B Virus Infection Market Drivers and Barriers

Scope of the Hepatitis B Virus Infection Pipeline Report

• Coverage- Global
• Hepatitis B Virus Infection Companies- Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics and others.
• Hepatitis B Virus Infection Pipeline Therapies- Peginterferon Alfacon-2, Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni], Entecavir, Tenofovir disoproxil fumarate (TDF), Bepirovirsen and others.
• Hepatitis B Virus Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hepatitis B Virus Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth pipeline report today! @ Hepatitis B Virus Infection Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. Hepatitis B Virus Infection: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hepatitis B Virus Infection– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Bepirovirsen: GSK
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. VIR 2218: Vir Biotechnology
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. AHB-137: Ausper Biopharma
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Hepatitis B Virus Infection Key Companies
21. Hepatitis B Virus Infection Key Products
22. Hepatitis B Virus Infection- Unmet Needs
23. Hepatitis B Virus Infection- Market Drivers and Barriers
24. Hepatitis B Virus Infection- Future Perspectives and Conclusion
25. Hepatitis B Virus Infection Analyst Views
26. Hepatitis B Virus Infection Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/hepatitis-b-virus-hbv-infection-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatitis B Virus Infection Pipeline Accelerates as 80+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “Exosomes Pipeline Insight 2026” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Exosomes pipeline landscape. It covers the Exosomes Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Exosomes Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Exosomes Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/exosomes-pipeline-insight

Key Takeaways from the Exosomes Pipeline Report

• On February 23, 2026- Direct Biologics LLC announced a Phase III, multicenter, randomized, double-blinded, placebo-controlled trial for the treatment of moderate-to-severe Acute Respiratory Distress Syndrome (ARDS). To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
• On January 20, 2026- Rion Inc. conducted a Phase 2a Multi-Center, Prospective, Randomized, Controlled Study aimed to evaluate the Safety and Efficacy of Topically Applied PEP-TISSEEL in Subjects with Diabetic Foot Ulcers (DFU).
• DelveInsight’s Exosomes Pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Exosomes treatment.
• The leading Exosomes Companies such as Celularity, EVerZom, Direct Biologics, Cambium Bio, Capricor Therapeutics, Aegle Therapeutics, Organicell, Evecxia, ArunaBio, Evox, Coya Therapeutics, ILIAS Biologics, EV Therapeutics, Nano24, and others.
• Promising Exosomes Therapies such as Olmutinib, Zofin, AGLE-102, and others.

Want to know which companies are leading innovation in Exosomes? Dive into the full pipeline insights @ Exosomes Clinical Trials Assessment

The Exosomes Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Exosomes Pipeline Report also highlights the unmet needs with respect to the Exosomes.

Exosomes Overview

Exosomes are classified as small (30–150 nm), phospholipid bilayer extracellular vehicles (EVs), which are released by both eukaryotic and prokaryotic cells for the purpose of intercellular communication and signaling. Initially, exosomes were identified as EVs used for excreting unwanted cellular waste–however, studies found that exosomes are important molecular mediators in cellular communication through their ability to transport proteins, metabolites, and various nucleic acids across the body.

Exosomes Emerging Drugs Profile

• ExoFlo: Direct Biologics

ExoFlo is an acellular human bone marrow mesenchymal stem cell (MSC) derived extracellular vesicle (EV) product produced with a proprietary EV platform technology by Direct Biologics, LLC. Containing signaling molecules from bone marrow MSCs, ExoFlo harnesses the anti-inflammatory and regenerative properties of bone marrow MSCs without the cost, complexity, and limitations of scale associated with stem cell transplantation. Preclinical studies of these extracellular vesicles secreted by bone marrow-derived mesenchymal stem cells (bmMSCs) suggest that they may have the ability to downregulate inflammation and upregulate tissue repair in humans. Currently, the drug is in the Phase III stage of its development for the treatment of Acute Respiratory Distress Syndrome.

• EXO-CD24: Nano24

EXO-CD24 (CovenD24), is an investigational drug being developed by Nano24. The company has developed a new anti-inflammatory drug, EXO-CD24, a combination of an immune checkpoint (CD24) and a delivery platform (exosomes). CD24 inhibits the NF-kB pathway and the production of cytokines/chemokines. EXO-CD24 discriminates damage from pathogen-associated molecular patterns (DAMPs and PAMPs) and therefore does not interfere with viral clearance. EXO-CD24 was produced and purified from CD24-expressing 293-TREx cells. Exosomes displaying murine CD24 (mCD24) were also created. EXO-CD24 is the new immunomodulator with promising efficacy without interfering with pathogen clearance. Nano24 developed CD24-enriched exosomes, named EXO-CD24, as a targeted therapy for hyperimmune activation in the context of COVID-19. CD24, which dampens cytokines and chemokines production while not interfering with pathogen clearance, is of particular interest as a therapeutic agent for virus-induced hyper-inflammation and ARDS. EXO-CD24, and its mouse homolog EXO-mCD24, is a new precision nanotechnology that can target and prevent the cytokine storm in the lungs. Nano24 is developing a pipeline of CD24-based exosomes aimed at treating COVID-19 with EXO-CD24, a therapeutic directly inhaled to the lungs, as well as a broad range of disease areas, spanning ARDS, respiratory, and autoimmune diseases. Currently, the drug is in the Phase II stage of Clinical trial evaluation for the treatment of Acute Respiratory Disease Syndrome (ARDS).

• AGLE-102: Aegle Therapeutics

AGLE 102 is an allogeneic-derived extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material, and regenerative healing factors to diseased and damaged tissue. The drug is being developed in the Phase I/II stage of its development for the treatment of Burns and Epidermolysis bullosa dystrophica. The drug is also in the preclinical stage of its development for the Graft vs. Host Disease.

• Progenza: Cambium Bio

Progenza is an off-the-shelf allogeneic stem cell product with the first targeted treatment being for knee osteoarthritis. The product is produced from mesenchymal stem cells (MSCs) from adipose (fat) tissue from a healthy donor who has been extensively screened. Progenza includes secretions from donor MSCs that improves viability and functionality of the cells after freezing. Adipose tissue is readily available from donors in large quantities and has significantly higher MSCs per gram of tissue than other tissue sources such as bone marrow or cord tissue. Adipose-derived MSCs also have the added advantage of showing greater capacity for expansion than MSCs from other tissue types. The MSCs are expanded through the company’s proprietary and scalable manufacturing process. The company has demonstrated the capacity to produce millions of therapeutic doses of Progenza from a single donor. When Progenza cells are injected into the damaged joint or tissue, the MSCs have the potential to reduce pain and inflammation and slow the progression of disease. As per the company’s pipeline, the drug is in the Phase I stage of Clinical trial evaluation for the treatment of Osteoarthritis.

• EV-101: EV Therapeutics

EV Therapeutics is a pre-clinical stage immuno-oncology biotechnology company devoted to developing first-in-class therapies based on modified tumor extracellular vesicles (mTEVs) to significantly transform cancer therapy and other unmet medical needs that are addressable with its proprietary technology platform. The leading candidate EV101, has demonstrated pre-clinical efficacy across solid tumor and advanced metastatic animal models both as a monotherapy and combination therapy with checkpoint inhibitors.

If you’re tracking ongoing Exosomes Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Exosomes Treatment Drugs

The Exosomes Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Exosomes with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Exosomes Treatment.
• Exosomes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Exosomes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Exosomes market.

Exosomes Companies

Celularity, EVerZom, Direct Biologics, Cambium Bio, Capricor Therapeutics, Aegle Therapeutics, Organicell, Evecxia, ArunaBio, Evox, Coya Therapeutics, ILIAS Biologics, EV Therapeutics, Nano24 and others.

Exosomes Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Exosomes Products have been categorized under various Molecule types such as,

• Oligonucleotide
• Peptide
• Small molecule

From emerging drug candidates to competitive intelligence, the Exosomes Pipeline Report covers it all – check it out now @ Exosomes Market Drivers and Barriers, and Future Perspectives

Scope of the Exosomes Pipeline Report

• Coverage- Global
• Exosomes Companies- Celularity, EVerZom, Direct Biologics, Cambium Bio, Capricor Therapeutics, Aegle Therapeutics, Organicell, Evecxia, ArunaBio, Evox, Coya Therapeutics, ILIAS Biologics, EV Therapeutics, Nano24 and others.
• Exosomes Therapies- Olmutinib, Zofin, AGLE-102, and others.
• Exosomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Exosomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Exosomes Treatment landscape in this detailed analysis @ Exosomes Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Exosomes: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Exosomes – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. ExoFlo: Direct Biologics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. EXO-CD24: Nano24
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Progenza: Cambium Bio
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. EV-101: EV Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Exosomes Key Companies
21. Exosomes Key Products
22. Exosomes – Unmet Needs
23. Exosomes – Market Drivers and Barriers
24. Exosomes – Future Perspectives and Conclusion
25. Exosomes Analyst Views
26. Exosomes Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/exosomes-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Exosomes Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight